Follow
Jane Davies
Jane Davies
Professor of Paediatric Respirology & Experimental Medicine
Verified email at imperial.ac.uk - Homepage
Title
Cited by
Cited by
Year
A CFTR potentiator in patients with cystic fibrosis and the G551D mutation
BW Ramsey, J Davies, NG McElvaney, E Tullis, SC Bell, P Dřevínek, ...
New England Journal of Medicine 365 (18), 1663-1672, 2011
23822011
Disordered microbial communities in asthmatic airways
M Hilty, C Burke, H Pedro, P Cardenas, A Bush, C Bossley, J Davies, ...
PloS one 5 (1), e8578, 2010
19382010
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
RECOVERY Collaborative Group
Lancet (London, England) 397 (10285), 1637, 2021
1721*2021
Lumacaftor–ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR
CE Wainwright, JS Elborn, BW Ramsey, G Marigowda, X Huang, M Cipolli, ...
New England Journal of Medicine 373 (3), 220-231, 2015
14942015
The future of cystic fibrosis care: a global perspective
SC Bell, MA Mall, H Gutierrez, M Macek, S Madge, JC Davies, PR Burgel, ...
The Lancet Respiratory Medicine 8 (1), 65-124, 2020
7562020
Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation
JC Davies, CE Wainwright, GJ Canny, MA Chilvers, MS Howenstine, ...
American journal of respiratory and critical care medicine 187 (11), 1219-1225, 2013
5992013
Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial
E Alton, M Stern, R Farley, A Jaffe, SL Chadwick, J Phillips, J Davies, ...
The Lancet 353 (9157), 947-954, 1999
5601999
Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial
EWFW Alton, DK Armstrong, D Ashby, KJ Bayfield, D Bilton, ...
The Lancet Respiratory Medicine 3 (9), 684-691, 2015
4972015
Tezacaftor–ivacaftor in residual-function heterozygotes with cystic fibrosis
SM Rowe, C Daines, FC Ringshausen, E Kerem, J Wilson, E Tullis, N Nair, ...
New England Journal of Medicine 377 (21), 2024-2035, 2017
4942017
Pseudomonas aeruginosa in cystic fibrosis: pathogenesis and persistence
JC Davies
Paediatric respiratory reviews 3 (2), 128-134, 2002
4222002
CpG-free plasmids confer reduced inflammation and sustained pulmonary gene expression
SC Hyde, IA Pringle, S Abdullah, AE Lawton, LA Davies, A Varathalingam, ...
Nature biotechnology 26 (5), 549-551, 2008
3682008
VX-659–tezacaftor–ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles
JC Davies, SM Moskowitz, C Brown, A Horsley, MA Mall, EF McKone, ...
New england journal of medicine 379 (17), 1599-1611, 2018
3382018
Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2–5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study
JC Davies, S Cunningham, WT Harris, A Lapey, WE Regelmann, ...
The Lancet Respiratory Medicine 4 (2), 107-115, 2016
3312016
Efficacy and safety of lumacaftor and ivacaftor in patients aged 6–11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial
F Ratjen, C Hug, G Marigowda, S Tian, X Huang, S Stanojevic, CE Milla, ...
The lancet Respiratory medicine 5 (7), 557-567, 2017
3162017
Lung clearance index is a sensitive, repeatable and practical measure of airways disease in adults with cystic fibrosis
AR Horsley, PM Gustafsson, KA Macleod, C Saunders, AP Greening, ...
Thorax 63 (2), 135-140, 2008
2792008
Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled …
J Davies, H Sheridan, N Bell, S Cunningham, SD Davis, JS Elborn, ...
The lancet Respiratory medicine 1 (8), 630-638, 2013
2612013
The Th17 pathway in cystic fibrosis lung disease
HL Tan, N Regamey, S Brown, A Bush, CM Lloyd, JC Davies
American journal of respiratory and critical care medicine 184 (2), 252-258, 2011
2512011
Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST)
EF McKone, D Borowitz, P Drevinek, M Griese, MW Konstan, ...
The lancet Respiratory medicine 2 (11), 902-910, 2014
2352014
Ivacaftor treatment of cystic fibrosis in children aged 12 to< 24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study
M Rosenfeld, CE Wainwright, M Higgins, LT Wang, C McKee, D Campbell, ...
The lancet respiratory medicine 6 (7), 545-553, 2018
2302018
Impaired innate interferon induction in severe therapy resistant atopic asthmatic children
MR Edwards, N Regamey, M Vareille, E Kieninger, A Gupta, A Shoemark, ...
Mucosal immunology 6 (4), 797-806, 2013
2292013
The system can't perform the operation now. Try again later.
Articles 1–20